CPRX RSI Chart
Last 7 days
-3.6%
Last 30 days
-9.6%
Last 90 days
-6.3%
Trailing 12 Months
21.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 411.3M | 0 | 0 | 0 |
2023 | 256.5M | 302.9M | 348.4M | 398.2M |
2022 | 153.7M | 170.5M | 191.8M | 214.2M |
2021 | 120.1M | 126.9M | 133.5M | 140.8M |
2020 | 119.0M | 119.8M | 118.2M | 119.1M |
2019 | 36.6M | 54.6M | 72.7M | 102.3M |
2018 | 0 | 0 | 0 | 18.5M |
2010 | 0 | 0 | 0 | 489.0K |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jun 07, 2024 | del carmen jeffrey | sold | -121,184 | 16.07 | -7,541 | chief commercial officer |
Jun 05, 2024 | ingenito gary | acquired | 320,800 | 4.01 | 80,000 | chief med. & reg. officer |
Jun 05, 2024 | ingenito gary | sold | -1,292,800 | 16.16 | -80,000 | chief med. & reg. officer |
Jun 04, 2024 | daly richard j | acquired | 160,400 | 4.01 | 40,000 | president and ceo |
Jun 04, 2024 | daly richard j | sold | -276,735 | 15.975 | -17,323 | president and ceo |
Jun 03, 2024 | harper molly | sold | -86,949 | 16.304 | -5,333 | - |
Apr 08, 2024 | tierney david s | acquired | 100,250 | 4.01 | 25,000 | - |
Apr 08, 2024 | tierney david s | sold | -392,000 | 15.68 | -25,000 | - |
Mar 27, 2024 | elsbernd brian | sold | -411,000 | 16.44 | -25,000 | chief compliance/legal officer |
Feb 15, 2024 | tierney david s | acquired | - | - | 4,000 | - |
Which funds bought or sold CPRX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Jun 04, 2024 | DekaBank Deutsche Girozentrale | new | - | 2,764,000 | 2,764,000 | -% |
May 29, 2024 | Opaleye Management Inc. | reduced | -20.11 | -5,426,690 | 16,009,400 | 3.49% |
May 28, 2024 | Boston Partners | reduced | -2.25 | -1,817,190 | 23,792,300 | 0.03% |
May 28, 2024 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | unchanged | - | -27,000 | 502,000 | -% |
May 24, 2024 | Cetera Investment Advisers | added | 31.78 | 91,532 | 458,259 | -% |
May 20, 2024 | Virtu Financial LLC | new | - | 191,000 | 191,000 | 0.01% |
May 20, 2024 | EMC Capital Management | reduced | -48.18 | -244,000 | 235,000 | 0.14% |
May 20, 2024 | CIM, LLC | added | 0.69 | 58,409 | 435,975 | 0.07% |
May 17, 2024 | Ikarian Capital, LLC | added | 2.48 | -240,468 | 8,263,070 | 0.91% |
May 16, 2024 | COMERICA BANK | added | 9.36 | 29,070 | 815,448 | -% |
Unveiling Catalyst Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2024 | vanguard group inc | 6.68% | 7,120,417 | SC 13G/A | |
Feb 12, 2024 | flynn james e | 8.34% | 8,888,901 | SC 13G/A | |
Jan 25, 2024 | state street corp | 6.37% | 6,787,332 | SC 13G/A | |
Jan 22, 2024 | blackrock inc. | 14.8% | 15,821,401 | SC 13G/A | |
Feb 14, 2023 | armistice capital, llc | 0% | 0 | SC 13G/A | |
Feb 10, 2023 | flynn james e | 5.65% | 5,884,448 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 6.50% | 6,768,741 | SC 13G | |
Feb 08, 2023 | state street corp | 7.57% | 7,873,314 | SC 13G/A | |
Jan 26, 2023 | blackrock inc. | 15.1% | 15,690,326 | SC 13G/A | |
Jan 20, 2023 | blackrock inc. | 15.1% | 15,690,326 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Jun 11, 2024 | 4 | Insider Trading | |
Jun 07, 2024 | 144 | Notice of Insider Sale Intent | |
Jun 07, 2024 | 4 | Insider Trading | |
Jun 05, 2024 | 144 | Notice of Insider Sale Intent | |
Jun 05, 2024 | 4 | Insider Trading | |
Jun 05, 2024 | 4 | Insider Trading | |
Jun 04, 2024 | 144 | Notice of Insider Sale Intent | |
Jun 03, 2024 | 144 | Notice of Insider Sale Intent | |
May 31, 2024 | S-8 | Employee Benefits Plan | |
May 31, 2024 | POS EX | POS EX |
Peers (Alternatives to Catalyst Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 53.7B | 6.8B | 8.51% | 7.74% | -8.99 | 7.84 | -64.45% | -224.75% |
HILS | 22.5B | 216.3K | -0.77% | 465779.94% | -2.5K | 104.0K | - | -8.13% |
ALNY | 20.3B | 2.0B | 8.81% | -20.73% | -61.09 | 10.13 | 75.20% | 68.82% |
BMRN | 15.9B | 2.5B | 3.83% | -12.90% | 77.15 | 6.41 | 13.74% | 186.89% |
INCY | 13.9B | 3.8B | 8.85% | -0.77% | 18.71 | 3.7 | 8.58% | 129.81% |
MID-CAP | ||||||||
BBIO | 5.2B | 107.9M | -7.07% | 79.45% | -9.53 | 48.09 | 54.84% | -28.31% |
APLS | 5.1B | 524.1M | 0.17% | -53.14% | -12.21 | 9.72 | 394.93% | 39.61% |
AXSM | 3.5B | 251.0M | -2.92% | -12.90% | -11.81 | 13.95 | 73.58% | -86.73% |
ARWR | 3.2B | 240.7M | 3.27% | -27.64% | -6.79 | 12.77 | -1.03% | -213.92% |
ACAD | 2.5B | 813.8M | -1.46% | -38.91% | -1.4K | 3.03 | 56.43% | 98.83% |
NVAX | 2.0B | 996.6M | 11.55% | 78.54% | -5.07 | 2.03 | -26.66% | 65.49% |
SMALL-CAP | ||||||||
CPRX | 1.8B | 411.3M | -9.60% | 21.75% | 27.32 | 4.32 | 60.38% | -34.49% |
CRBP | 534.3M | 881.7K | 13.28% | 545.16% | -15.83 | 481.06 | -77.61% | 33.36% |
INO | 235.5M | 4.2M | -30.45% | 48.53% | -1.89 | 56.62 | -66.30% | 48.24% |
IBIO | 22.1M | 2.1M | 36.17% | 264.31% | -0.95 | 7.61 | -13.45% | 69.54% |
Catalyst Pharmaceuticals Inc News
Income Statement (Quarterly) | (In Thousands) | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -10.9% | 99.00 | 111 | 103 | 100 | 85.00 | 61.00 | 57.00 | 53.00 | 43.00 | 38.00 | 36.00 | 36.00 | 30.00 | 31.00 | 29.00 | 30.00 | 29.00 | 30.00 | 31.00 | 29.00 | 12.00 |
Operating Expenses | 3.6% | 71.00 | 69.00 | 140 | 53.00 | 50.00 | 30.00 | 32.00 | 25.00 | 26.00 | 26.00 | 22.00 | 21.00 | 20.00 | - | - | - | - | - | - | 18.00 | 13.00 |
S&GA Expenses | 11.7% | 47.00 | 42.00 | 34.00 | 28.00 | 30.00 | 14.00 | 14.00 | 13.00 | 16.00 | 13.00 | 12.00 | 12.00 | 13.00 | 13.00 | 10.00 | 11.00 | 10.00 | 11.00 | 8.00 | 9.00 | 8.00 |
R&D Expenses | 30.9% | 3.00 | 2.00 | 84.00 | 4.00 | 4.00 | 4.00 | 8.00 | 4.00 | 3.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 4.00 | 6.00 | 5.00 | 5.00 | 3.00 |
EBITDA Margin | -11.5% | 0.21* | 0.24* | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | - | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Income Taxes | -51.0% | 6.00 | 12.00 | -7.26 | 11.00 | 8.00 | 8.00 | 3.00 | 7.00 | 4.00 | 4.00 | 4.00 | 4.00 | 2.00 | -2.71 | -31.60 | 1.00 | 1.00 | 0.00 | 1.00 | 0.00 | - |
Earnings Before Taxes | -37.7% | 29.00 | 47.00 | -38.02 | 49.00 | 37.00 | 33.00 | 26.00 | 28.00 | 17.00 | 13.00 | 14.00 | 16.00 | 10.00 | 9.00 | 12.00 | 10.00 | 11.00 | 8.00 | 14.00 | 11.00 | -0.64 |
EBT Margin | -11.6% | 0.21* | 0.24* | 0.23* | 0.48* | 0.49* | 0.49* | 0.44* | 0.43* | 0.39* | 0.37* | 0.36* | 0.36* | 0.34* | - | - | - | - | - | - | - | - |
Net Income | -33.2% | 23.00 | 35.00 | -30.76 | 38.00 | 30.00 | 25.00 | 23.00 | 22.00 | 13.00 | 9.00 | 10.00 | 12.00 | 8.00 | 11.00 | 43.00 | 10.00 | 10.00 | 8.00 | 14.00 | 11.00 | -0.64 |
Net Income Margin | -11.7% | 0.16* | 0.18* | 0.18* | 0.38* | 0.39* | 0.39* | 0.35* | 0.32* | 0.29* | 0.28* | 0.31* | 0.59* | 0.60* | - | - | - | - | - | - | - | - |
Free Cashflow | -42.9% | 32.00 | 56.00 | 45.00 | 31.00 | 12.00 | 40.00 | 41.00 | 26.00 | 8.00 | 19.00 | 22.00 | 16.00 | 3.00 | - | - | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 37.6% | 647 | 470 | 413 | 444 | 407 | 376 | 333 | 267 | 247 | 238 | 223 | 209 | 197 | 192 | 175 | 131 | 118 | 112 | 97.00 | 78.00 | 61.00 |
Current Assets | 84.5% | 405 | 219 | 192 | 241 | 199 | 321 | 276 | 243 | 221 | 210 | 193 | 176 | 162 | 159 | 143 | 131 | 117 | 111 | 91.00 | 72.00 | 55.00 |
Cash Equivalents | 125.5% | 310 | 138 | 121 | 179 | 148 | 298 | 256 | 211 | 178 | 171 | 155 | 135 | 127 | 130 | 117 | 115 | 102 | 90.00 | 45.00 | 23.00 | 19.00 |
Inventory | 27.5% | 20.00 | 16.00 | 9.00 | 11.00 | 10.00 | 7.00 | 7.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.00 | 4.00 | 5.00 | 5.00 | 2.00 | 2.00 | 2.00 | 1.00 | 0.00 | 0.00 |
Net PPE | 9.5% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 3.7% | 85.00 | 82.00 | 65.00 | 69.00 | 74.00 | 75.00 | 63.00 | 26.00 | 27.00 | 31.00 | 25.00 | 20.00 | 19.00 | 23.00 | 18.00 | 20.00 | 18.00 | 25.00 | 19.00 | 15.00 | 10.00 |
Current Liabilities | 4.6% | 80.00 | 76.00 | 58.00 | 53.00 | 57.00 | 58.00 | 45.00 | 22.00 | 23.00 | 27.00 | 21.00 | 16.00 | 14.00 | 23.00 | 18.00 | 20.00 | 18.00 | 24.00 | 18.00 | 14.00 | 9.00 |
Shareholder's Equity | 44.7% | 561 | 388 | 349 | 375 | 334 | 300 | 270 | 241 | 220 | 207 | 199 | 189 | 179 | 170 | 157 | 111 | 100 | 88.00 | 78.00 | 63.00 | 51.00 |
Retained Earnings | 19.2% | 145 | 121 | 86.00 | 117 | 79.00 | 50.00 | 24.00 | 2.00 | -15.62 | -26.31 | -32.54 | -37.82 | -46.33 | -53.70 | -65.14 | -108 | -118 | -128 | -136 | -150 | -161 |
Additional Paid-In Capital | 56.4% | 417 | 266 | 262 | 258 | 254 | 250 | 246 | 239 | 236 | 233 | 231 | 227 | 225 | 223 | 222 | 220 | 218 | 216 | 214 | 213 | 212 |
Shares Outstanding | 10.2% | 118 | 107 | 107 | 107 | 106 | 105 | 103 | 103 | 103 | 103 | 103 | 103 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 1,341 | - | - | - | 666 | - | - | - | 551,582 | - | - | - | 445 | - | - | - | 368 | - |
Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -42.6% | 31,925 | 55,648 | 45,128 | 30,754 | 12,070 | 40,077 | 41,301 | 26,191 | 8,478 | 19,176 | 21,707 | 15,675 | 3,814 | 13,105 | 11,451 | 13,265 | 7,213 | 12,292 | 16,263 | 14,074 | -8,016 |
Share Based Compensation | 94.1% | 8,248 | 4,250 | 3,810 | 3,298 | 2,892 | 1,926 | 2,055 | 2,023 | 1,903 | 1,472 | 1,512 | 1,518 | 1,571 | 1,470 | 1,478 | 1,794 | 1,519 | 1,150 | 817 | 925 | 933 |
Cashflow From Investing | 99.5% | -199 | -38,318 | -92,817 | - | -162,367 | - | -132 | - | - | -41.00 | -68.00 | -4,001 | -6,911 | - | -10,011 | - | 5,000 | 31,659 | 5,047 | -9,930 | 10,449 |
Cashflow From Financing | 21310.4% | 141,049 | -665 | -10,127 | -214 | 149 | 2,253 | 3,984 | -2,992 | -1,551 | -2,526 | -2,098 | -3,707 | 188 | 26.00 | 614 | 36.00 | 26.00 | 578 | 256 | 193 | 89.00 |
Buy Backs | - | - | - | - | - | - | - | -7.00 | 4,356 | 2,551 | 3,070 | 5,100 | 3,668 | 293 | - | - | - | - | - | - | - | - |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) $ in Thousands | 3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |||
Revenues: | ||||
Total revenues | $ 98,509 | $ 85,366 | ||
Operating costs and expenses: | ||||
Cost of sales | [1] | 12,520 | 9,946 | |
Research and development | 2,581 | 3,562 | ||
Selling, general and administrative | [1] | 46,938 | 29,718 | |
Amortization of intangible assets | 9,344 | 6,531 | ||
Total operating costs and expenses | 71,383 | 49,757 | ||
Operating income | 27,126 | 35,609 | ||
Other income, net | 1,963 | 1,704 | ||
Net income before income taxes | 29,089 | 37,313 | ||
Income tax provision | 5,814 | 7,745 | ||
Net income | $ 23,275 | $ 29,568 | ||
Net income per share: | ||||
Basic | $ 0.2 | $ 0.28 | ||
Diluted | $ 0.19 | $ 0.26 | ||
Weighted average shares outstanding: | ||||
Basic | 116,806,117 | 105,561,229 | ||
Diluted | 123,403,626 | 113,986,129 | ||
Net income | $ 23,275 | $ 29,568 | ||
Other comprehensive income (Note 4): | ||||
Unrealized gain (loss) on available-for-sale securities, net of tax of $4 and $5, respectively | (14) | (13) | ||
Comprehensive income | 23,261 | 29,555 | ||
Product revenue, net [Member] | ||||
Revenues: | ||||
Total revenues | 98,441 | 85,304 | ||
License and other revenue [Member] | ||||
Revenues: | ||||
Total revenues | $ 68 | $ 62 | ||
|
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 310,411 | $ 137,636 |
Accounts receivable, net | 60,493 | 53,514 |
Inventory | 19,953 | 15,644 |
Prepaid expenses and other current assets | 13,745 | 12,535 |
Total current assets | 404,602 | 219,329 |
Operating lease right-of-use asset | 2,440 | 2,508 |
Property and equipment, net | 1,308 | 1,195 |
License and acquired intangibles, net | 184,705 | 194,049 |
Deferred tax assets, net | 38,276 | 36,544 |
Investment in equity securities | 15,345 | 16,489 |
Total assets | 646,676 | 470,114 |
Current Liabilities: | ||
Accounts payable | 10,261 | 14,795 |
Accrued expenses and other liabilities | 69,305 | 61,268 |
Total current liabilities | 79,566 | 76,063 |
Operating lease liability, net of current portion | 3,091 | 3,188 |
Other non-current liabilities | 2,607 | 2,982 |
Total liabilities | 85,264 | 82,233 |
Commitments and contingencies (Note 12) | ||
Stockholders' equity: | ||
Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value, 200,000,000 shares authorized; 118,029,526 shares and 107,121,549 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 118 | 107 |
Additional paid-in capital | 416,747 | 266,488 |
Retained earnings | 144,547 | 121,272 |
Accumulated other comprehensive income (Note 4) | 0 | 14 |
Total stockholders' equity | 561,412 | 387,881 |
Total liabilities and stockholders' equity | $ 646,676 | $ 470,114 |
 CEO | Mr. Patrick J. McEnany |
---|---|
 WEBSITE | catalystpharma.com |
 INDUSTRY | Biotechnology |
 EMPLOYEES | 82 |